Oral Dosing Of Glp-1 Compounds

Patent No. EP2991671 (titled "Oral Dosing Of Glp-1 Compounds") was filed by Novo Nordisk on May 2, 2014. The application was issued on Aug 15, 2018.

Patent Summary

Solid composition comprising a GLP-1 peptide and an enhancer for use as a medicament by oral administration. The composition comprises a GLP-1 peptide and an enhancer for use as a medicament by oral administration.

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2991671

NOVO NORDISK
Application Number
EP14721834A
Filing Date
May 2, 2014
Status
Revoked
Mar 22, 2024
Publication Date
Aug 15, 2018